These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10656221)

  • 41. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease.
    Cone CJ; Bachyrycz AM; Murata GH
    Ann Pharmacother; 2010 Oct; 44(10):1655-9. PubMed ID: 20647417
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Glimepiride-induced acute hepatitis].
    Dusoleil A; Condat B; Sobesky R; Pelletier G; Buffet C
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1096-7. PubMed ID: 10592884
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanism of hepatotoxicity due to black cohosh (Cimicifuga racemosa): histological, immunohistochemical and electron microscopy analysis of two liver biopsies with clinical correlation.
    Enbom ET; Le MD; Oesterich L; Rutgers J; French SW
    Exp Mol Pathol; 2014 Jun; 96(3):279-83. PubMed ID: 24657312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
    Rupprecht E; König E; Limmer J
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature.
    Feng X; Yuan L; Hu Y; Zhu Y; Yang F; Jiang L; Yan R; Luo Y; Zhao E; Liu C; Wang Y; Li Q; Cao X; Li Q; Ma J
    Endocr Metab Immune Disord Drug Targets; 2016; 16(4):230-234. PubMed ID: 28017142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
    Braatvedt GD
    N Z Med J; 1997 May; 110(1044):189-90. PubMed ID: 9201206
    [No Abstract]   [Full Text] [Related]  

  • 49. A case of drug-induced hepatic injury associated with sitagliptin.
    Toyoda-Akui M; Yokomori H; Kaneko F; Shimizu Y; Takeuchi H; Tahara K; Motoori T; Ohbu M; Oda M; Hibi T
    Intern Med; 2011; 50(9):1015-20. PubMed ID: 21532224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Enalapril (Reniten)-associated toxic hepatitis].
    Hürlimann R; Binek J; Oehlschlegel C; Hammer B
    Schweiz Med Wochenschr; 1994 Jul; 124(29):1276-80. PubMed ID: 8066414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study.
    Du J; Kleefstra N; Schrijnders D; Groenier KH; de Bock GH; Landman GWD
    Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1596-1605. PubMed ID: 32404443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.
    Tessier D; Maheux P; Khalil A; Fülöp T
    Metabolism; 1999 Jul; 48(7):897-903. PubMed ID: 10421233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study.
    Mailhot J
    Clin Ther; 1993; 15(6):1060-8. PubMed ID: 8111803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erythroderma secondary to gliclazide: a case report.
    Ozuguz P; Kacar SD; Ozuguz U; Karaca S; Tokyol C
    Cutan Ocul Toxicol; 2014 Dec; 33(4):342-4. PubMed ID: 24641117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Granulomatous hepatitis associated with glyburide.
    Saw D; Pitman E; Maung M; Savasatit P; Wasserman D; Yeung CK
    Dig Dis Sci; 1996 Feb; 41(2):322-5. PubMed ID: 8601376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hypoglycemia].
    Gupta PS; Green AN; Chowdhury TA
    Praxis (Bern 1994); 2011 Oct; 100(21):1303-5. PubMed ID: 22012756
    [No Abstract]   [Full Text] [Related]  

  • 58. Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report.
    Gunaratne K; Austin E; Wu PE
    BMC Res Notes; 2018 May; 11(1):331. PubMed ID: 29784014
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center.
    Ettel M; Gonzalez GA; Gera S; Eze O; Sigal S; Park JS; Xu R
    Hum Pathol; 2017 Oct; 68():92-98. PubMed ID: 28873351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.